摘要
利拉鲁肽为胰高血糖素样肽1类似物,且可通过促进机体白色脂肪组织向棕色脂肪组织转化,消耗机体过剩能量,还可以延迟胃排空速度,增加肥胖者胃饱腹感,进而控制肥胖者体重。多项研究表明,利拉鲁肽具有良好的减重作用,且安全。在控制肥胖者体重的同时,利拉鲁肽能改善肥胖并发症如糖尿病、睡眠呼吸暂停综合征、多囊卵巢综合征、心脑血管疾病、肾脏疾病等的临床症状,在肥胖人群中有一定的应用前景。
As a glucagon-like peptide 1 analogue, liraglutide can promote the transformation of white adipose tissue into brown adipose tissue, consume excess energy of body, delay the speed of gastric emptying, and increase the feeling of fullness in obese patients, therefore it can control the weight. Many studies have shown that liraglutide has a good effect on weight loss and it is safe. While controlling the weight of obese people, liraglutide can improve the clinical symptoms of obesity complications such as diabetes, sleep apnea syndrome, polycystic ovary syndrome, cardio-cerebrovascular disease,kidney disease. It has a certain application prospect in obese people.
作者
刘亚丹
段飞
王颖
王泽瑾
万红
燕树勋
LIU Ya-dan;DUAN Fei;WANG Ying;WANG Ze-jin;WAN Hong;YAN Shu-xun(He-nan University of Chinese Medicine,Zhengzhou HE-NAN 450000,China;The First Afiliated Hospital,He-nanUniversitly of Chinese Medicine,LZhengzhou HE-MAN 450008,China;The First Afiliated Hospital,Zhengzhou Uniersity,Zhengzhou HE-NAN 450052,China;Medical College,Hebei University of Engineering,Handan HEBE1056038,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2021年第12期815-821,共7页
Chinese Journal of New Drugs and Clinical Remedies
基金
河南省中医药科学研究专项课题(2018JDZX018)
河南省中医药传承与创新人才工程(仲景工程)中医药拔尖人才(CZ0237-02)
郑州市科技惠民计划(2021KJHM0017)。
关键词
利拉鲁肽
肥胖症
减肥药
并发症
liraglutide
obesity
anti-obesity agents
complication
